Once-daily 1 g ceftriaxone optimizes exposure in patients with septic shock and hypoalbuminemia receiving continuous veno-venous hemodiafiltration
Published inEuropean journal of clinical pharmacology, vol. 77, no. 8, p. 1169-1180
Publication date2021-08
First online date2021-02-09
Abstract
Keywords
- Ceftriaxone
- Continuous veno-venous hemodiafiltration
- Critically ill patients
- Hypoalbuminemia
- Pharmacokinetics
- Septic shock
- Aged
- Anti-Bacterial Agents / administration & dosage
- Anti-Bacterial Agents / pharmacokinetics
- Anti-Bacterial Agents / therapeutic use
- Ceftriaxone / administration & dosage
- Ceftriaxone / pharmacokinetics
- Ceftriaxone / therapeutic use
- Continuous Renal Replacement Therapy
- Critical Illness
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Monitoring
- Female
- Humans
- Hypoalbuminemia / etiology
- Hypoalbuminemia / metabolism
- Male
- Microbial Sensitivity Tests
- Middle Aged
- Monte Carlo Method
- Prospective Studies
- Shock, Septic / complications
- Shock, Septic / drug therapy
- Spain
Affiliation
Research group
Citation (ISO format)
ULLDEMOLINS, Marta et al. Once-daily 1 g ceftriaxone optimizes exposure in patients with septic shock and hypoalbuminemia receiving continuous veno-venous hemodiafiltration. In: European journal of clinical pharmacology, 2021, vol. 77, n° 8, p. 1169–1180. doi: 10.1007/s00228-021-03100-5
Main files (1)
Article (Accepted version)
![accessLevelRestricted](assets/images/access-level-restricted.png)
Secondary files (3)
Identifiers
- PID : unige:169663
- DOI : 10.1007/s00228-021-03100-5
- PMID : 33559708
ISSN of the journal0031-6970